Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAPN1 | P07384 | 2/20 | 0.59 |
| ▸ | CTSB | P07858 | 2/20 | 0.59 |
| ▸ | DPP3 | Q9NY33 | 5/20 | 0.58 |
| ▸ | NTSR2 | O95665 | 1/20 | 0.54 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.54 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.54 |
| ▸ | KISS1R | Q969F8 | 3/20 | 0.50 |
| ▸ | CALCRL | Q16602 | 1/20 | 0.49 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.48 |
| ▸ | REN | P00797 | 1/20 | 0.48 |
| ▸ | F13A1 | P00488 | 1/20 | 0.47 |
| ▸ | TGM2 | P21980 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30392472 | 0.91 | KISS1R (0.58) | CAPN1CTSBDPP3KISS1RCALCRL | |
| SCHEMBL30392074 | 0.91 | KISS1R (0.58) | CAPN1CTSBDPP3KISS1RCALCRL | |
| Spinorphin SCHEMBL25217672 | 0.91 | KISS1R (0.60) | CAPN1CTSBDPP3KISS1RSLC6A2 | |
| Spinorphin SCHEMBL25273730 | 0.91 | KISS1R (0.60) | CAPN1CTSBDPP3KISS1RSLC6A2 | |
| Spinorphin SCHEMBL29977609 | 0.91 | KISS1R (0.60) | CAPN1CTSBDPP3KISS1RSLC6A2 | |
| SCHEMBL31326864 | 0.87 | DPP3 (0.56) | CAPN1CTSBDPP3NTSR2NTSR1 | |
| SCHEMBL30441566 | 0.86 | CAPN1 (0.63) | CAPN1CTSBDPP3NTSR2NTSR1 | |
| SCHEMBL29437939 | 0.85 | CAPN1 (0.60) | CAPN1CTSBDPP3NTSR2NTSR1 | |
| SCHEMBL29973443 | 0.84 | DPP3 (0.57) | CAPN1CTSBDPP3NTSR2NTSR1 | |
| SCHEMBL30974182 | 0.84 | NTSR2 (0.70) | CAPN1CTSBDPP3NTSR2NTSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4426280-B1 | PROTECTION AGAINST ARTHROPOD PARASITES WITH PURINERGIC RECEPTOR (OPR) ANTAGONISTS | GURBA ALEXANDRE (CH) | 2026-03-18 | — | — | EP | disclosed |
| US-20250057791-A1 | PROTECTION AGAINST ARTHROPOD PARASITES WITH PURINERGIC RECEPTOR (OPR) ANTAGONISTS | GURBA ALEXANDRE (CH) | 2025-02-20 | — | — | US | disclosed |
| EP-4426280-A1 | PROTECTION AGAINST ARTHROPOD PARASITES WITH PURINERGIC RECEPTOR (OPR) ANTAGONISTS | Gurba, Alexandre (CH) | 2024-09-11 | — | — | EP | disclosed |
| WO-2023111938-A1 | PROTECTION AGAINST ARTHROPOD PARASITES WITH PURINERGIC RECEPTOR (OPR) ANTAGONISTS | GURBA, Alexandre (CH) | 2023-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250057791-A1 | PROTECTION AGAINST ARTHROPOD PARASITES WITH PURINERGIC RECEPTOR (OPR) ANTAGONISTS | P2RX2, P2RX3, P2RX1 | CAPN1 3322/4885CTSB 1322/4885DPP3 1395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.